Q3 earnings beat estimates, but shares dip as 2025 sales outlook narrows. Get key highlights and pharma market insights.

Merck boosts its full-year outlook as third-quarter earnings top estimates following strong demand for its blockbuster cancer ...

Merck shares dipped after strong earnings and higher profit guidance, as the company narrowed its 2025 sales forecast amid ...

Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit.

Merck's Q3 2025 results saw huge growth in Winrevair and Capvaxive sales. Check out why I maintain my Strong Buy rating on ...

Global pharmaceutical company Merck (NYSE:MRK) will be reporting earnings this Thursday morning. Here’s what you need to know ...

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling ...

Merck MRK will report its third-quarter 2025 earnings on Oct. 30, before market open. The Zacks Consensus Estimate for ...

Investing.com - Merck&Co (NYSE: MRK) reported third quarter EPS of $2.58, $0.23 better than the analyst estimate of $2.35. Revenue for the quarter came in at $17.28B versus the consensus estimate of ...

Moderna is down 35.3% since the beginning of the year, and at $27.16 per share, it is trading 50.3% below its 52-week high of ...

Going by the price/earnings ratio, GILD’s shares currently trade at ... GILD has also collaborated with Merck MRK to evaluate the investigational combination of islatravir and lenacapavir for the ...

Third quarter earnings season is ramping up, and analysts expect S&P 500 companies grew their profits by 8% during the quarter.